Editas Medicine Inc (NAS:EDIT)
$ 5.62 -0.27 (-4.58%) Market Cap: 462.18 Mil Enterprise Value: 222.35 Mil PE Ratio: 0 PB Ratio: 1.65 GF Score: 52/100

Editas Medicine Inc RUBY trial of EDIT-301 Transcript

Jun 12, 2023 / 12:00PM GMT
Release Date Price: $9.93 (+2.69%)
Cristi Barnett
Editas Medicine, Inc. - Corporate Communications & IR

Good morning, everyone, and thank you for joining the EDIT-301 clinical update webinar. This webinar is being recorded and can be accessed in the future through this same link or through the Investors section of the company's website. After the webinar, the call will be open to Q&A. (Operator Instructions).

As a reminder, various remarks that we make during the presentation today about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC as updated by our subsequent filings.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot